{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.4","value":"191.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"385"}],"units":"Participants"}],"title":"Week 0: peak concentration"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.2","value":"120.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"}],"units":"Participants"}],"title":"Week 8: trough concentration"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.9","value":"177.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"225"}],"units":"Participants"}],"title":"Week 24: trough concentration"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.6","value":"373.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"}],"units":"Participants"}],"title":"Week 24: peak concentration"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"67.4","value":"186.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"}],"units":"Participants"}],"title":"Week 48: trough concentration"}],"denoms":[{"counts":[{"groupId":"OG000","value":"473"}],"units":"Participants"}],"description":"To evaluate PK, blood samples were collected pre-dose and post-dose and trough and peak serum concentrations of durvalumab, respectively, were determined. Pre-dose samples were taken within 60 minutes before infusion and post-dose samples were taken within 10 minutes after the end of infusion.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients in the durvalumab (MEDI4736) monotherapy group were to receive durvalumab 10 mg/kg Q2W via intravenous infusion for up to 12 months.","id":"OG000","title":"Durvalumab (MEDI4736)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all patients who received at least 1 dose of durvalumab per the protocol, for whom any post-dose data were available, and who did not violate or deviate from the protocol in ways that would significantly affect the PK analyses.","reportingStatus":"POSTED","timeFrame":"Samples were collected pre-dose on Day 1 (Week 0), Week 8, Week 24 and Week 48, and post-dose on Day 1 (Week 0) and Week 24. Analysis performed at 22 Mar 2018 DCO.","title":"Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations","type":"SECONDARY","unitOfMeasure":"Micrograms per milliliter"}